Edesa Biotech, Inc. (EDSA): Price and Financial Metrics


Edesa Biotech, Inc. (EDSA): $8.14

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EDSA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

EDSA POWR Grades


  • EDSA scores best on the Sentiment dimension, with a Sentiment rank ahead of 52.65% of US stocks.
  • EDSA's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
  • EDSA ranks lowest in Quality; there it ranks in the 1st percentile.

EDSA Stock Summary

  • For EDSA, its debt to operating expenses ratio is greater than that reported by merely 5.19% of US equities we're observing.
  • EDSA's price/sales ratio is 217,921.4; that's higher than the P/S ratio of 99.98% of US stocks.
  • Revenue growth over the past 12 months for Edesa Biotech Inc comes in at -99.93%, a number that bests merely 0.66% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Edesa Biotech Inc, a group of peers worth examining would be BEAM, FSR, ARNA, BLU, and TRIL.
  • EDSA's SEC filings can be seen here. And to visit Edesa Biotech Inc's official web site, go to edesabiotech.com.

EDSA Valuation Summary

  • EDSA's price/sales ratio is 77800; this is 685362.56% higher than that of the median Healthcare stock.
  • EDSA's EV/EBIT ratio has moved up 1.7 over the prior 71 months.
  • Over the past 71 months, EDSA's price/sales ratio has gone up 77598.7.

Below are key valuation metrics over time for EDSA.

Stock Date P/S P/B P/E EV/EBIT
EDSA 2021-08-31 77800 4.9 -6.6 -6.0
EDSA 2021-08-30 68900 4.4 -5.9 -5.2
EDSA 2021-08-27 66400 4.2 -5.7 -5.0
EDSA 2021-08-26 65300 4.1 -5.6 -4.9
EDSA 2021-08-25 62000 3.9 -5.3 -4.6
EDSA 2021-08-24 59100 3.7 -5.0 -4.4

EDSA Growth Metrics

  • Its year over year net cashflow from operations growth rate is now at -136.83%.
  • Its 5 year revenue growth rate is now at -39.16%.
  • The 3 year net income to common stockholders growth rate now stands at -50.04%.
Over the past 30 months, EDSA's revenue has gone down $243,895.

The table below shows EDSA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.0005 -14.98255 -11.71879
2021-03-31 0.110485 -13.21624 -8.656066
2020-12-31 0.221001 -7.207157 -7.925623
2020-09-30 0.328801 -4.98634 -6.36423
2020-06-30 0.738671 -4.639829 -5.269248
2020-03-31 0.629186 -5.580533 -4.839021

EDSA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EDSA has a Quality Grade of F, ranking ahead of 2.01% of graded US stocks.
  • EDSA's asset turnover comes in at 0 -- ranking 441st of 681 Pharmaceutical Products stocks.
  • NWBO, BMRN, and ORMP are the stocks whose asset turnover ratios are most correlated with EDSA.

The table below shows EDSA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 -3.628 -3.858
2021-03-31 0.008 0.966 -5.275
2020-12-31 0.024 0.937 -45.852
2020-09-30 0.041 0.946 -36.783
2020-06-30 0.108 0.842 -17.301
2020-03-31 0.098 0.817 -17.585

EDSA Price Target

For more insight on analysts targets of EDSA, see our EDSA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.00 Average Broker Recommendation 1.5 (Moderate Buy)

EDSA Stock Price Chart Interactive Chart >

Price chart for EDSA

EDSA Price/Volume Stats

Current price $8.14 52-week high $12.00
Prev. close $8.14 52-week low $4.05
Day low $8.02 Volume 437,500
Day high $8.40 Avg. volume 1,288,574
50-day MA $6.50 Dividend yield N/A
200-day MA $5.87 Market Cap 107.90M

Edesa Biotech, Inc. (EDSA) Company Bio


Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.


EDSA Latest News Stream


Event/Time News Detail
Loading, please wait...

EDSA Latest Social Stream


Loading social stream, please wait...

View Full EDSA Social Stream

Latest EDSA News From Around the Web

Below are the latest news stories about Edesa Biotech Inc that investors may wish to consider to help them evaluate EDSA as an investment opportunity.

As Edesa Biotech, Inc. (NASDAQ:EDSA) gains 11%, insiders who bought last year may be wishing they had bet higher

Edesa Biotech, Inc. ( NASDAQ:EDSA ) insiders who bought shares over the past year were rewarded handsomely last week...

Yahoo | October 9, 2021

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Introduction Edesa Biotech (EDSA) is a Canadian clinical-stage biotech company. EDSA has two lead candidates, EB05 and EB01. Both are in later stage clinical studies. EB05 is a monoclonal antibody therapy for Acute Respiratory Distress Syndrome ((ARDS)). ARDS is a life-threatening form of respiratory failure, and the leading cause of...

C. C. Abbott on Seeking Alpha | September 22, 2021

50 Biggest Movers From Yesterday

Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock rallied over 100% yesterday. uCloudlink Group Inc. (NASDAQ: UCL) dropped 17.4% to close at $5.08 after gaining 14% on Monday. Movano Inc. (NASDAQ: MOVE) fell 16.4% to settle at $3.22. KULR Technology Group, Inc. (NYSE: KULR) declined 13.2% to settle at $2.37. ATIF Holdings Limited (NASDAQ: ATIF) fell 12.9% to settle at $3.4850. RBC Be

Yahoo | September 22, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | September 21, 2021

EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday

Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride.

Chris MacDonald on InvestorPlace | September 20, 2021

Read More 'EDSA' Stories Here

EDSA Price Returns

1-mo -1.21%
3-mo 57.14%
6-mo 45.10%
1-year 26.01%
3-year 10.30%
5-year -90.45%
YTD 91.53%
2020 3.66%
2019 -24.91%
2018 -83.95%
2017 -60.10%
2016 -68.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8153 seconds.